The House Judiciary Committee issued subpoenas on February 9, 2026 to Elevance Health Inc. (ELV) and a group of other large health insurers, formally requesting documents and testimony about how the companies handled federal Affordable Care Act (ACA) premium subsidies. The subpoenas were publicly announced on February 10, 2026 and set a February 23 deadline for the insurers to provide the requested information.
The subpoenas target a broad coalition of insurers that includes Blue Shield of California, Centene, CVS Health, GuideWell, Health Care Service Corp., Kaiser Permanente, and Oscar Health, in addition to Elevance. The investigation is driven by a December 2023 Government Accountability Office report that uncovered billions of dollars in unreconciled ACA subsidies and flagged potential fraud. The committee is examining whether insurers misrepresented subsidy eligibility or improperly collected funds, and whether legislative reforms are needed to strengthen fraud prevention.
Elevance Health’s Q4 2025 results, released on January 28, 2026, provide context for the subpoena. The company reported operating revenue of $49.3 billion, up 10% year‑over‑year, and adjusted diluted earnings per share of $3.33, beating analyst estimates of $3.10 by $0.23. The benefit‑expense ratio rose to 93.5% from 91.3% in Q3, driven by higher medical costs in ACA and Medicaid plans. The Health Benefits segment generated $41.8 billion in revenue, up 11% YoY, while the Carelon services segment grew 27% to $18.7 billion.
Management’s outlook reflects the cost pressures that prompted the guidance cut for FY 2026. CEO Gail Boudreaux said the company is “focusing on affordability and pricing discipline” and reaffirmed a 2026 EPS guidance of at least $25.50, below the analyst consensus of $26.80. The guidance downgrade signals management’s concern about rising medical costs and margin compression, but the company remains confident it can return to 12% adjusted EPS growth in 2027. The company’s Q4 revenue miss of $0.52 billion, relative to the $49.82 billion consensus, was attributed to slower premium growth in the individual market and higher claim costs.
Analysts and investors reacted to the subpoena and the financial results with caution. The downgrade of the 2026 guidance and the revenue miss were cited as primary drivers of negative sentiment, while the EPS beat was noted as a positive but insufficient offset. The market’s focus on margin outlook and cost inflation underscores the broader headwinds facing the ACA and Medicaid segments, which are experiencing higher benefit‑expense ratios and membership attrition.
The subpoena adds regulatory scrutiny to a company already navigating cost pressures. While the Q4 earnings beat suggests effective cost control, the rising benefit‑expense ratio and lower guidance highlight ongoing margin compression. The investigation could expose potential compliance gaps that may lead to penalties or reputational damage, but it also forces Elevance to tighten its subsidy reporting processes. In the long term, the company’s diversified platform—Health Benefits, Carelon services, and Medicare Advantage—provides resilience, yet the ACA and Medicaid headwinds will continue to test its profitability and growth trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.